secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039793
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q2 revenue $24.7M (up 91% YoY); cash runway into H2 2025 after $30M financing
--------------------------------------------------------------------------------

- Cash, equivalents & investments $180.9M at June 30, 2023; $30M gross financing from BVF closed July 2023.
- Revenue $24.7M (vs $12.9M Q2 2022) driven by BMS collaboration; R&D expenses fell to $20.7M.
- CX-904 (EGFRxCD3) Phase 1 dose escalation data anticipated first half of 2024; backfill cohorts by end 2023.
- IND filings for wholly-owned CX-2051 (EpCAM ADC) and CX-801 (IFNa2b) expected Q4 2023.
- Appointed Dr. Wayne Chu as CMO; promoted Dawn Benson to SVP Quality and Product Manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017023039793/0000950170-23-039793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017023039793/ctmx-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer